Management care improvement of people living with HIV: definition of a targeted clinical pathway in a University Hospital of South Italy.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
02 09 2021
02 09 2021
Historique:
received:
06
03
2021
accepted:
20
05
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
In the world 37,9 billions live with Human Immunodeficiency Virus and, despite the availability of retroviral therapy, they have an higher risk to acquire other infectious diseases and to develop severe complications. According to several guidelines their immunization is crucial but only some center have developed a specific scheduled pathway and vaccination coverage is very low. Aim of this study is: a)incentivize the active and free of charge offer of vaccines and increase of immunization coverage; b) application and implementation of a shared clinical pathway avoiding reluctance, embarrassment or shame by patients for their condition; d) instauration of an empathic relationship between doctor and patient; e) evaluation of side effects. A prospective study was conducted from October 2019 to February 2020 at the University Hospital G. Martino of Messina. Inclusion criteria were: age over 18; absence of other diseases; absence of immunization against HBV or HAV; CD4 count for live attenuated viral vaccines of 350/uL and for other vaccine 200/uL. A specific scheduled pathway was adopted for every patient. Statistical analysis was performed with Excel software. 86 patients were enrolled (74.4% were males, 79.1% were Italian; mean age=4013.3 SD). An increase in administration was observed between 2018 and 2019 (+164.3% for flu and for other vaccines +370%). The higher increase was observed for HPV one. No-one received DTpa, MMRV or Zoster vaccine. The undertook clinical pathway showed the relevance of specific management of these patients and the need to increase the vaccination offer.
Sections du résumé
BACKGROUND AND AIM
In the world 37,9 billions live with Human Immunodeficiency Virus and, despite the availability of retroviral therapy, they have an higher risk to acquire other infectious diseases and to develop severe complications. According to several guidelines their immunization is crucial but only some center have developed a specific scheduled pathway and vaccination coverage is very low. Aim of this study is: a)incentivize the active and free of charge offer of vaccines and increase of immunization coverage; b) application and implementation of a shared clinical pathway avoiding reluctance, embarrassment or shame by patients for their condition; d) instauration of an empathic relationship between doctor and patient; e) evaluation of side effects.
METHODS
A prospective study was conducted from October 2019 to February 2020 at the University Hospital G. Martino of Messina. Inclusion criteria were: age over 18; absence of other diseases; absence of immunization against HBV or HAV; CD4 count for live attenuated viral vaccines of 350/uL and for other vaccine 200/uL. A specific scheduled pathway was adopted for every patient. Statistical analysis was performed with Excel software.
RESULTS
86 patients were enrolled (74.4% were males, 79.1% were Italian; mean age=4013.3 SD). An increase in administration was observed between 2018 and 2019 (+164.3% for flu and for other vaccines +370%). The higher increase was observed for HPV one. No-one received DTpa, MMRV or Zoster vaccine.
CONCLUSIONS
The undertook clinical pathway showed the relevance of specific management of these patients and the need to increase the vaccination offer.
Identifiants
pubmed: 34487078
doi: 10.23750/abm.v92i4.11425
pmc: PMC8477122
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021244Références
Hum Vaccin Immunother. 2015;11(1):263-9
pubmed: 25483544
Curr HIV/AIDS Rep. 2011 Dec;8(4):269-76
pubmed: 21837443
J Acquir Immune Defic Syndr. 2010 Jul;54(3):248-57
pubmed: 20658748
AIDS Behav. 2020 Aug;24(8):2244-2249
pubmed: 32303925
Hum Vaccin Immunother. 2019;15(2):295-304
pubmed: 30111224
Front Public Health. 2018 Mar 12;6:70
pubmed: 29594092
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1653-1656
pubmed: 33382675
Ann Ig. 2019 Mar-Apr;31(2 Supple 1):13-24
pubmed: 30994160
Vaccines (Basel). 2019 Nov 03;7(4):
pubmed: 31684158
AIDS Behav. 2020 Mar;24(3):667-681
pubmed: 31486008
Acta Biomed. 2019 Sep 13;90(9-S):45-53
pubmed: 31517889
Ann Ig. 2018 Jul-Aug;30(4 Supple 1):33-37
pubmed: 30062378
Vaccine. 2014 Jul 31;32(35):4558-4564
pubmed: 24951870
Cent Eur J Public Health. 2019 Sep;27(3):217-222
pubmed: 31580557
Eur Neuropsychopharmacol. 2009 May;19(5):305-8
pubmed: 19269795
Braz J Infect Dis. 2017 Sep - Oct;21(5):515-519
pubmed: 28579170
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
Syst Rev. 2014 Sep 11;3:101
pubmed: 25212760
Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):7163-7182
pubmed: 31486519
Hum Vaccin Immunother. 2019;15(2):305-306
pubmed: 30303429
Vaccine. 2012 Jul 20;30(34):5172-8
pubmed: 21414380
AIDS Patient Care STDS. 2014 Aug;28(8):397-410
pubmed: 25029589
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Vaccines (Basel). 2020 Nov 16;8(4):
pubmed: 33207626